Wall Street analysts expect Acceleron Pharma (NASDAQ:XLRN) to report earnings per share of ($0.64) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Acceleron Pharma’s earnings, with the highest EPS estimate coming in at ($0.60) and the lowest estimate coming in at ($0.68). Acceleron Pharma reported earnings of ($0.66) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 3%. The business is expected to announce its next earnings results on Monday, May 14th.
On average, analysts expect that Acceleron Pharma will report full-year earnings of ($2.50) per share for the current year, with EPS estimates ranging from ($3.13) to ($2.11). For the next financial year, analysts expect that the business will report earnings of ($2.04) per share, with EPS estimates ranging from ($2.92) to ($1.16). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that follow Acceleron Pharma.
Acceleron Pharma (NASDAQ:XLRN) last posted its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.02). The firm had revenue of $3.71 million for the quarter, compared to analysts’ expectations of $3.39 million. Acceleron Pharma had a negative net margin of 804.49% and a negative return on equity of 38.71%.
Shares of NASDAQ:XLRN traded down $1.14 during trading on Friday, hitting $36.47. 323,161 shares of the stock traded hands, compared to its average volume of 316,693. The firm has a market cap of $1,741.82, a price-to-earnings ratio of -13.77 and a beta of 1.43. Acceleron Pharma has a 52-week low of $24.37 and a 52-week high of $46.93.
In other news, SVP John D. Quisel sold 1,204 shares of the company’s stock in a transaction on Tuesday, April 3rd. The shares were sold at an average price of $38.40, for a total transaction of $46,233.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard F. Pops sold 37,500 shares of the company’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $41.42, for a total transaction of $1,553,250.00. Following the sale, the director now directly owns 68,750 shares of the company’s stock, valued at approximately $2,847,625. The disclosure for this sale can be found here. Insiders have sold 58,304 shares of company stock valued at $2,425,062 in the last ninety days. Insiders own 3.90% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. grew its holdings in shares of Acceleron Pharma by 10.1% during the fourth quarter. BlackRock Inc. now owns 4,732,135 shares of the biopharmaceutical company’s stock worth $200,832,000 after buying an additional 434,123 shares in the last quarter. Perceptive Advisors LLC grew its holdings in shares of Acceleron Pharma by 127.2% during the third quarter. Perceptive Advisors LLC now owns 1,616,259 shares of the biopharmaceutical company’s stock worth $60,319,000 after buying an additional 905,000 shares in the last quarter. Farallon Capital Management LLC grew its holdings in shares of Acceleron Pharma by 13.0% during the fourth quarter. Farallon Capital Management LLC now owns 1,088,000 shares of the biopharmaceutical company’s stock worth $46,175,000 after buying an additional 125,000 shares in the last quarter. Carillon Tower Advisers Inc. acquired a new position in shares of Acceleron Pharma during the 4th quarter valued at about $40,014,000. Finally, Artal Group S.A. boosted its position in shares of Acceleron Pharma by 7.1% during the 4th quarter. Artal Group S.A. now owns 750,000 shares of the biopharmaceutical company’s stock valued at $31,830,000 after acquiring an additional 50,000 shares during the last quarter. 88.23% of the stock is owned by institutional investors and hedge funds.
About Acceleron Pharma
Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.